Volume 26, Number 7—July 2020
Dispatch
Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand
Table 1
Demographics, baseline characteristics, illness histories, laboratory values and treatment therapies of confirmed COVID-19 patients in Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand, 2020*
Demographics | Patient no. |
Total, % | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10† | 11 | |||
Age, y/sex | 61/F | 74/F | 68/M | 66/F | 57/F | 34/M | 61/M | 63/M | 28/F | 51/M | 49/M | 55 M/45 F | |
Ethnicity | CH | CH | CH | CH | CH | CH | CH | CH | CH | TH | TH | 82 CH/18 TH | |
Occupation |
Ret |
Ret |
Ret |
Ret |
Ret |
EE |
Ret |
Ret |
Tour guide |
Taxi driver |
Officer |
54 Ret/46 other |
|
Detected through airport screening | Y | Y | Y | N | N | N | N | N | N | N | N | 27 Y/73 N | |
Detected through contact tracing | N | N | N | Y | N | N | N | N | N | N | N | 9 Y/91 N | |
Detected after patient voluntarily sought medical care | N | N | N | N | Y | Y | Y | Y | Y | Y | Y | 64 Y/36 N | |
Visited Hunan Seafood Market |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
0 |
|
Underlying conditions | |||||||||||||
Diabetes | N | N | N | N | N | Y | N | N | N | Y | N | 18 Y/82 N | |
Hypertension | Y | Y | N | Y | N | N | N | N | N | Y | N | 36 Y/64 N | |
COPD | N | N | N | N | N | N | N | N | N | N | N | 0 | |
Asthma | N | N | N | N | N | N | N | N | N | N | N | 0 | |
Cancer | N | N | N | N | N | N | N | N | N | N | N | 0 | |
Cardiovascular disease | N | Y | N | Y | N | N | N | Y | N | N | N | 27 Y/73 N | |
Cerebrovascular disease | N | N | N | N | N | N | N | Y | N | N | N | 9 Y/91 N | |
Chronic liver disease | N | N | N | N | N | N | N | N | N | N | Y | 9 Y/91 N | |
Any chronic condition |
Y |
Y |
N |
Y |
N |
Y |
N |
Y |
N |
Y |
Y |
64 Y/36 N |
|
Current smoker | N | N | N | N | N | N | N | N | N | N | N | 0 | |
Pregnant |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
N |
NA |
NA |
0 |
|
Laboratory values at time of admission (reference range) | |||||||||||||
Leukocytes ×109/L (4.5–8) | 1.9↓ | 3.3↓ | 4 | 3.6 | 3.9 | 3.4↓ | 5.8 | 4.1 | 4.9 | 5.8 | 2.5↓ | ||
Neutrophils, % (36–70) | 48 | 64 | 66 | 63 | 56 | 80↑ | 63 | 83 | 73↑ | 58 | 54 | ||
Lymphocytes, % (23–57) | 40 | 19↓ | 25 | 25 | 33 | 1↓ | 30 | 16↓ | 23 | 31 | 30 | ||
Platelets ×106 /μL (140–400) | 127↓ | 16.4↓ | 12.6↓ | 177 | 167 | 169 | 168 | 18.4↓ | 153 | 368 | 167 | ||
Hemoglobin, g/dL (11–14) | 13.3 | 12.8 | 11.5 | 13.1 | 13.2 | 13.3 | 15.3↑ | 13.8 | 11.4 | 14 | 14.8↑ | ||
Hematocrit, % (35–41) | 38 | 38 | 33↓ | 37 | 37.9 | 38 | 45↑ | 39 | 34 | 41 | 43↑ | ||
ALT, U/L (0–31) | 18 | 27 | 18 | 83↑ | 23 | 16 | 22 | 22 | 24 | 24 | 26 | ||
AST, U/L (0–31) |
14 |
12 |
15 |
47↑ |
16 |
19 |
20 |
14 |
25 |
16 |
22 |
||
Other diagnostics | |||||||||||||
Oxygen saturation on room air at admission | 98 | 97 | 95 | 98 | 99 | 99 | 98 | 99 | 96 | 91↓ | 97 | ||
Results from Biofire-33 multiplex PCR‡ | |||||||||||||
Haemophilus influenzae | + | + | – | – | + | + | – | – | – | – | – | ||
Adenovirus | – | + | – | – | – | – | – | – | – | – | – | ||
Influenza A | – | – | – | – | – | – | + | – | – | – | – | ||
Klebsiella pneumoniae |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
+ |
||
Treatments | |||||||||||||
Antimicrobial drugs, dose | |||||||||||||
Ceftriaxone, 2 g 4×/d IV | 1 | 0 | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 7 | 0 | ||
Ceftriaxone, 2 g/d orally | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
AMOX/CLAV, 2 g 4×/d orally | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | ||
Oseltamivir, 150 mg 4×/d orally | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | ||
Nasal cannula, 5 L, no. days |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
||
Duration of signs and symptoms reported at admission, d | Median (IQR)/ mean (SD) | ||||||||||||
Cough | 1 | 1 | 1 | 0 | 2 | 1 | 4 | 2 | 3 | 8 | 5 | 2 (1–4)/2.5 (2.3) | |
Malaise or fatigue | 4 | 2 | 4 | 0 | 2 | 4 | 13 | 2 | 3 | 5 | 5 | 4 (2–5)/4.0 (3.3) | |
Fever | 2 | 2 | 4 | 0 | 3 | 4 | 4 | 2 | 2 | 8 | 5 | 3 (2–4)/3.3 (2.1) | |
Sore throat | 4 | 0 | 3 | 0 | 3 | 2 | 4 | 2 | 3 | 7 | 5 | 3 (2–4)/3.0 (2.0) | |
Rhinorrhea | 2 | 2 | 4 | 0 | 2 | 1 | 3 | 2 | 2 | 2 | 4 | 2 (2–3)/2.2 (1.2) | |
Headache | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 3 | 1 (0–2)/1.3 (1.6) | |
Vomiting | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 (0–1)/0.3 (0.5) | |
Diarrhea | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0/0.2 (0.4) |
*ALT, alanine aminotransferase; AMOX/CLAV, amoxicillin/clavulanate; AST, aspartate aminotransferase; COVID-19, coronavirus disease; CH, Chinese; EE, electrical engineer; IV, intravenous; NA, not applicable; Ret, retired; TH, Thai; ↓, low; ↑, high; +, positive; –, negative.
†(2)
‡BioFire Diagnostics (https://www.biofiredx.com)
References
- Department of Medical Sciences, Ministry of Public Health, Thailand. Diagnostic detection of novel coronavirus 2019 by real time RT-PCR. Version 0. 23 January 2020. [cited 2020 Feb 16] https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4
- Department of Disease Control. Thailand. Guidelines for medical practice, diagnosis, treatment and prevention of healthcare-associated infection in response to patients with COVID-19 infection, revised version dated 16 February 2020 [cited 2020 Feb 21]. https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/G_CPG_en.pdf
- Department of Disease Control, Ministry of Public Health, Thailand. Novel coronavirus 2019 pneumonia situation: Thailand situation update on 15 February 2020 [cited 2020 Feb 16] https://ddc.moph.go.th/viralpneumonia/eng/file/situation/situation-no43-150263.pdf
Page created: April 08, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.